Veterinary Medicines

The introduction of the worldwide regulatory scheme for registration of Veterinary Medicinal Products (VICH) is currently ongoing.  This scheme is concerned with the possible environmental impact of veterinary medicinal products (VMPs). The physical, chemical and biological qualities of the residues of some VMPs may result in environmental persistence and/or ecotoxicological effects. For those VMPs though to be of concern after a Phase 1 Environmnetal Impact Assessment (EIA), a VICH Phase II EIA will be required.

Brixham Laboratory can perform the environmental effects and fate studies that will be required by Phase II of the VICH risk assessment process.

We will help you to understand the resullts and interpret the data, both of which are critical for the accurate and reliable establishment of predicted environmental concentrations (PECs), predicted no observed effect concentrations (PNECs) and ultimately a robust EIA.